Latest news with #Hansa
Hindustan Times
03-06-2025
- Business
- Hindustan Times
Hansa, Jamnapari, Barbari—The ‘supermodels' of Bakrid goat shopping
With Eid-ul-Adha (Bakrid) just days away, Lucknow's goat markets are alive with activity as buyers scour for the finest breeds. From the sturdy Barbari to the regal Hansa, customers are drawn to unique features, beauty, build, and rarity, with prices already soaring. The Barbari breed commands ₹1 lakh, while the Hansa fetches around ₹75,000, yet neither is the most expensive. Sellers claim that as the festival nears, rates for both high-end and affordable breeds will climb sharply. The real showstoppers, however, are the Beetal and African Boer breeds, which dominate the premium segment. Averaging between ₹4-5 lakh, these goats can even sell for several lakhs, depending on demand. Ghazanfar Abbas, a seasoned goat trader from Barabanki, notes that buyers from across Uttar Pradesh flock near Lucknow's Jogger Park for their prized picks. 'The rush hasn't peaked yet, it's the final two or three days before Bakrid when the real crowd arrives,' he says. The Beetal, a popular Indian breed found in Punjab and Pakistan's Punjab region, is known for its impressive height of four feet and weight of up to 280 kg. With its striking white eyes and sturdy build, it often features in livestock competitions. 'Last year, a buyer from Kanpur paid over ₹21 lakh for two Beetals,' Ghazanfar recalls. Then there's the African Boer, towering at nearly five feet, weighing 200-250 kg, and known for its aggressive demeanour. 'Its meat sells at ₹2,000 per kg, and the live animal starts at ₹4 lakh, with prices rising based on buyer interest,' Ghazanfar added. For those seeking beauty over brawn, the Barbari, native to Agra and Mathura, stands out with its dense fur, frills, and distinctive pink skin, another goat seller said. Meanwhile, the Hansa and Jamnapari breeds from Chambal and Etawah, along with Rajasthan's Sirohi, Gujri, and Ajmeri goats, attract buyers for their height and striking appearance.
NDTV
27-05-2025
- Science
- NDTV
India To Develop Indigenous Electric Trainer Aircraft 'E-Hansa' For Rs 2 Crore
New Delhi: India has initiated the process to develop electric Hansa (E-Hansa), a next-generation two-seater electric trainer aircraft, Union Minister Dr Jitendra Singh said on Tuesday. The indigenously developed E-Hansa trainer aircraft is expected to cost around Rs 2 crore, significantly less than imported alternatives. Dr Singh said that it is a matter of pride that the new aircraft is being indigenously developed by the CSIR institute of "National Aerospace Laboratories" (NAL) Bengaluru. The E-HANSA is part of the larger HANSA-3 (NG) trainer aircraft programme, which is designed to be a cost-effective and indigenous option for pilot training in India. India's E-Hansa aircraft will also mark a key step toward India's green aviation goals and use of green or clean energy fuel in running our aircrafts, said the minister while chairing high-level review meeting with science department secretaries. Further, the meeting focused on performance assessment, implementation status of prior decisions, and setting the course for transformative reforms in India's science and technology ecosystem. Stressing the need for commercialisation of indigenous technologies, Dr Singh called for greater public-private partnerships (PPP). He directed the National Research Development Corporation (NRDC) to emulate the successful models of DBT-BIRAC and IN-SPACe for technology transfer and private sector engagement. Dr Singh reiterated the importance of standardised tech transfer protocols, ease of doing business, and promoting Indian R&D under the ethos of "Vasudhaiva Kutumbakam". Commending ISRO for the successful SPADEX mission, he noted that the docking and undocking capability tested is vital to India's upcoming Gaganyaan human spaceflight. He also lauded ISRO's substantial role in Operation Sindoor, stating, "Every Indian is proud of you." He shared that ISRO is currently collaborating with 40 Union Ministries and 28 State Governments, with a series of upcoming missions lined up. Regarding India's contribution to the Axiom Space Mission, Dr Singh informed that Group Captain Shubhanshu Shukla's visit to the International Space Station (ISS) will include seven microgravity experiments, further boosting India's space science profile.
Yahoo
14-05-2025
- Health
- Yahoo
Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS
LUND, Sweden, May 14, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) at the Peripheral Nerve Society (PNS) Annual Meeting, taking place 17-20 May in Edinburgh, Scotland. Hansa communicated the results from the 15-HMedIdeS-09 study in December 2024. Professor Shahram Attarian, Head of Department of Neuromuscular Diseases and ALS, Hopitaux Universitaires de Marseille (APHM) and International Coordinating Principal Investigator will present data from 15-HMedIdeS-09 Phase 2 study at the 2025 PNS Annual Meeting. Hitto Kaufmann, Chief R&D Officer, Hansa Biopharma said, "We are pleased to be able to share more detail around the positive data from our 15-HMedIdeS-09 Phase 2 study, which demonstrated the significant potential imlifidase could have in combination with standard of care IVIg for patients with GBS. We know that IgG is a key driver of inflammatory attacks on peripheral nerves and has been clinically linked to the severity and progression of GBS, and that there is a clear and urgent need for new and faster treatment options in GBS. This data offers meaningful insights to help advance the understanding of IgG in GBS and improve patient care." Lead Author Abstract Title Presentation Details Pr Shahram Attarian "Outcome in patients with severe Guillain-Barré Syndrome treated with imlifidase and standard-of-care immunoglobulin" – Oral presentation 18 May, 11:25. Part of the Richard A.C. Hughes Symposium: Clinical Highlights Hansa's Phase 2 15-HMedIdes-09 open-label, single arm study was performed across multi-centers in the UK, France, and the Netherlands evaluating the safety, tolerability, and efficacy of a single dose of imlifidase (0.25 mg/kg) in 30 adult GBS patients in combination with standard of care (SoC) intravenous immunoglobulin (IVIg). The administration of imlifidase prior to SoC in patients with GBS was considered to be safe and well tolerated. --- ENDS --- Contacts for more information: Evan Ballantyne, Chief Financial OfficerIR@ Stephanie Kenney, VP Global Corporate Affairsmedia@ Notes to editors About imlifidase Imlifidase is a unique antibody-cleaving enzyme originating from Streptococcus pyogenes that specifically targets IgG and inhibits IgG-mediated immune response.1 It has a rapid onset of action, cleaving IgG-antibodies and inhibiting their activity within hours after administration. Imlifidase has conditional marketing approval in Europe and is marketed under the trade name IDEFIRIX® for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.1 About imlifidase and autoimmune diseases Autoimmune diseases form a group of serious diseases caused by the immune system attacking the body. In many autoimmune diseases the immune system mistakenly recognizes the body's own proteins, as foreign and mounts an immune response, creating antibodies to attack the body's own cells and tissues.2-4 Pathogenic IgG can contribute to a broad spectrum of autoimmune diseases. Hansa Biopharma is exploring how imlifidase and HNSA-5487 may be able to prevent or slow the progression of these diseases and their debilitating, life-threatening symptoms. Imlifidase is currently being studied in the following autoimmune diseases: anti-glomerular basement membrane (anti-GBM) disease and Guillain-Barré Syndrome (GBS). HNSA-5487 is moving quickly into the clinical phase focusing on patients with myasthenia gravis (MG) and potentially other neuro-autoimmune diseases. About Guillain-Barré Syndrome Guillain-Barré Syndrome (GBS) is a rare, acute, paralyzing, inflammatory disease of the peripheral nervous system caused by the immune system damaging nerve cells and structures. It affects 1-2 in 100,000 people annually.5 In GBS, rapid onset and progression of muscle weakness occurs and can lead to severe paralysis of the arms and legs. Approximately 25 percent of patients require mechanical ventilation for days to months and 20 percent are unable to walk after six months.6-8 Even with current standard of care - either plasma exchange or IVIg therapy - GBS is fatal in 3-7% of cases.6-8 Most GBS patients also have sensory disturbance (tingling or numbness or ataxia) and pain, and some patients have double vision or problems with swallowing. GBS may also involve the respiratory muscles, leading to intensive care unit (ICU) admission and mechanical ventilation.9 About Hansa Biopharma Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at and follow us on LinkedIn. ©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved. References European Medicines Agency. Idefirix® summary of product characteristics. Available at: Angum F, et al. The Prevalence of Autoimmune Disorders in Women: A Narrative Review. Cureus. 2020 May 13;12(5):e8094. doi: 10.7759/cureus.8094. Wang L, et al. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015 Oct;278(4):369-95. doi: 10.1111/joim.12395. Ma H, Murphy C, Loscher CE and O'Kennedy R (2022) Autoantibodies – enemies, and/or potential allies? Front. Immunol. 13:953726. doi: 10.3389/fimmu.2022.953726 McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32(2):150-63. doi: 10.1159/000184748. Epub 2008 Dec 17. PMID: D, et al. Neurology. 2000 27;54(12):2311-5 Leonhard SE, Papri N, Querol L, Rinaldi S, Shahrizaila N, Jacobs BC. Guillain-Barré syndrome. Nat Rev Dis Primers. 2024 Dec 19;10(1):97. doi: 10.1038/s41572-024-00580-4. PMID: 39702645. Fletcher DD, Lawn ND, Wolter TD, Wijdicks EF. Long-term outcome in patients with Guillain-Barre syndrome requiring mechanical ventilation. Neurology. 2000;54(12):2311–5. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014 Aug;10(8):469-82. doi: 10.1038/nrneurol.2014.121. Epub 2014 Jul 15. PMID: 25023340. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016 Aug 13;388(10045):717-27. doi: 10.1016/S0140-6736(16)00339-1. Epub 2016 Mar 2. PMID: 26948435. This information was brought to you by Cision The following files are available for download: 250514 HNSA - PNS Meeting View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Indian Express
11-05-2025
- Politics
- Indian Express
National Technology Day: All you need to know about India's nuclear might for UPSC exam
Take a look at the essential events, concepts, terms, quotes, or phenomena every day and brush up your knowledge. Here's your knowledge nugget for today on National Technology Day, focused on India's nuclear journey from a broader perspective. India celebrates National Technology Day annually on May 11 to commemorate the successful nuclear test at Pokhran in 1998, which marked India's significant achievements in science and technology and emphasised its pivotal role in solidifying the nation's position as a global leader in technological innovation. In this context, let's know about the history of India's nuclear tests, associated personalities and India's nuclear doctrine. 1. On May 11, 1998, three very special technological advances were showcased by India's scientists and engineers — Operation Shakti, also known widely as Pokhran-II nuclear tests; the successful test firing of Trishul missile; and the first test flight of the indigenously developed aircraft Hansa. 2. The euphoria of demonstrations of these technologies was such that the then Prime Minister Atal Bihari Vajpayee added 'Jai Vigyan' (Hail Science) to Lal Bahadur Shastri's popular slogan of 'Jai Jawan, Jai Kisan' (Hail the soldier and the farmer). 3. Former Prime Minister Atal Bihari Vajpayee also designated May 11 as National Technology Day in India to commemorate the historic Pokhran-II nuclear tests. The following year, on May 11, 1999, the Council for Technology organised the inaugural celebration of National Technology Day. 4. India is currently among eight countries in the world that have a publicly known nuclear weapons programme. At the time of India's independence, the country's leaders were opposed to fully embracing nuclear weapons. Just two years before in 1945, the world had witnessed the horrific nuclear bombings of Hiroshima and Nagasaki. Mahatma Gandhi called the use of nuclear weapons morally unacceptable. His protege and India's first Prime Minister, Jawaharlal Nehru, was also sceptical, but kept the door open for future consideration. 1. This future beckoned early, as India's defeat in the 1962 Sino-Indian War and and China's subsequent nuclear bomb test at Lop Nor in 1964 gave rise to legitimate fears about national security. Things were further accelerated, when in 1965, India went to war with Pakistan once again, with China openly supporting Pakistan this time. 2. Also, post 1974, Pakistan had actively started acquiring nuclear weapons. China was sharing technology and materials with Pakistan, and it was public knowledge. Effectively, India was faced with two nuclear capable adversaries, and needed to take steps towards building self-sufficiency. 1. By the 1970s, India was capable of conducting a nuclear bomb test. Bhaba's successor at the DAE, Vikram Sarabhai, had worked to significantly broaden India's nuclear technology and now the question was more of political will, especially in context of a global order extremely wary of nuclear proliferation. 2. On May 18, 1974, with support from Indira, India carried out its first nuclear test at the Pokhran test site. Pokhran-I, codenamed Operation Smiling Buddha, would be billed as a 'peaceful nuclear explosion', with 'few military implications'. 3. However, the world was not willing to buy India's version of the story. There was near-universal condemnation and countries like the US and Canada imposed significant international sanctions on India. These sanctions would be a major setback for India's nuclear journey, and majorly decelerate its progress. 1. Beyond international sanctions, India's nuclear journey was also hobbled by domestic political instability. The Emergency of 1975 and Prime Minister Morarji Desai's opposition to nuclear weapons brought the programme to a grinding halt. 2. After a few years of domestic turmoil when the political will to conduct nuclear testing was wanting, in 1998, the National Democratic Alliance (NDA) led by the BJP came to power under the leadership of Atal Bihari Vajpayee. One of the key promises in its manifesto was to 'induct nuclear weapons' into India's arsenal. 3. In March 1998, Pakistan launched the Ghauri missile – built with assistance from China. Two months later, India responded with Operation Shakti. 4. Notably, while the 1974 tests were ostensibly done for peaceful purposes, the 1998 tests were the culmination of India's nuclear weaponisation process. Consequently, the Indian Government declared itself as a state possessing nuclear weapons following Pokhran-II. 5. While the tests in 1998 also invited sanctions from some countries (like the US), the condemnation was far from universal like in 1974. In context of India's fast-growing economy and market potential, India was able to stand its ground and thus cement its status as a dominant nation state. Shekhar Mande ( former director general of Council of Scientific and Industrial Research) explains– 1. 'Since 1998, the country has continued steadily in its journey of technological developments. Among the visible examples of India's impactful technological progress are the digital payment gateways that have democratised financial transactions like never before, and exemplify India's leadership in the world in this area. 2. Lesser-known milestones that have quietly been achieved are making of indigenous BioJet fuels, mapping of subsurface water channels for sustainable use of water, making of indigenous light combat aircraft, development of variety of crops by traditional methods of breeding, digitisation of many aspects of trade, and moving firmly towards a Hydrogen economy. 3. The recent push for infrastructural development, including promotion of use of domestic and industrial waste in it, and its spectacular results, are already making headlines. By steadily reducing energy dependence on natural resources and by promoting renewable energy, India is already in the league of nations where carbon footprint in the energy sector is likely to reduce dramatically. 4. Challenges, however, remain in many areas, including urban infrastructure and planning, containing air, water and soil pollution, slowing down rural to urban migrations, diversification of agricultural produce, judicious use of water resources, and promotion of AI/ ML technologies in all industrial segments.' 1. On January 4, 2003, when Vajpayee was India's Prime Minister, the Cabinet Committee on Security (CCS) met to review the progress in operationalizing the country's nuclear doctrine. An official release issued that day summarized the decisions that were being put in the public domain. 2. Among the major points in the doctrine was 'a posture of No First Use', which was described as follows: 'Nuclear weapons will only be used in retaliation against a nuclear attack on Indian territory or on Indian forces anywhere'. However, the doctrine made it clear that India's 'nuclear retaliation to a first strike will be massive and designed to inflict unacceptable damage'. Also, 'in the event of a major attack against India, or Indian forces anywhere, by biological or chemical weapons, India will retain the option of retaliating with nuclear weapons'. The doctrine also said: * Nuclear retaliatory attacks can only be authorised by the civilian political leadership through the Nuclear Command Authority. The Nuclear Command Authority comprises a Political Council and an Executive Council. The Political Council is chaired by the Prime Minister. * India would not use nuclear weapons against non-nuclear weapon states. * India would continue to put strict controls on the export of nuclear and missile related materials and technologies, participate in the Fissile Material Cutoff Treaty negotiations, and continue to observe the moratorium on nuclear tests. * India remains committed to the goal of a nuclear weapons free world, through global, verifiable and non-discriminatory nuclear disarmament. 1. The NPT is an international treaty whose objective is to prevent the spread of nuclear weapons and weapons technology, to foster the peaceful uses of nuclear energy, and to further the goal of disarmament. 2. In 1968, the NPT came into existence. The treaty defines nuclear-weapon states as those that have built and tested a nuclear explosive device before January 1, 1967 – the US, Russia (formerly USSR), the UK, France and China – and effectively disallows any other state from acquiring nuclear weapons. 3. While the treaty has been signed by almost every country in the world, India is one of the few non-signatories. Consider the following countries: (UPSC CSE 2015) 1. China. 2. France 3. India 4. Israel 5. Pakistan Which among the above are Nuclear Weapons States as recognized by the Treaty on the Non-Proliferation of Nuclear Weapons, commonly known as Nuclear Non-Proliferation Treaty (NPT)? (a) 1 and 2 only (b) 1, 3, 4 and 5 only (c) 2, 4 and 5 only (d) 1, 2, 3, 4 and 5 (Sources: Leaps India has taken, and what remains to be done, Nuclear scientist Anil Kakodkar explains: How Pokhran happened, 25th anniversary of Pokhran-II: India's journey to become a nuclear power, India's doctrine of Nuclear No First Use) Subscribe to our UPSC newsletter. Stay updated with the latest UPSC articles by joining our Telegram channel – Indian Express UPSC Hub, and follow us on Instagram and X. 🚨 Click Here to read the UPSC Essentials magazine for April 2025. Share your views and suggestions in the comment box or at Manas Srivastava 🚨 Roshni Yadav is a Deputy Copy Editor with The Indian Express. She is an alumna of the University of Delhi and Jawaharlal Nehru University, where she pursued her graduation and post-graduation in Political Science. She has over five years of work experience in ed-tech and media. At The Indian Express, she writes for the UPSC section. Her interests lie in national and international affairs, governance, economy, and social issues. You can contact her via email: ... Read More
Time of India
04-05-2025
- Entertainment
- Time of India
#WorldLaughterDay: How to tell a good joke is an art, says Supriya Pathak
While Hansa, 's character in the franchise, remains one of the most memorable comic characters on Indian television, Pathak surprises us when she says, 'I am not a good joke teller at all. Tired of too many ads? go ad free now Every time I tell a joke, it falls flat. How to tell a good joke is also an art, not everyone can crack it.' On , the veteran actress talks about why playing Hansa was tough, and why she feels doing good comedy 'is the toughest job.' Excerpts: 'What Charlie Chaplin did was extremely difficult' I feel doing comedy is the toughest job. An actor can use glycerin and cry to convince the audience of a sad emotion. However, making someone laugh is extremely difficult. As an actor, if I am having fun while playing a character, then the audience will enjoy it too. In my latest Gujarati film ( ), while it's not an out-and-out comedy, there are fun moments and I enjoy playing such characters. While doing a comic scene, if even one actor messes up the comic timing, the joke falls flat. I feel when it comes to comedies that have double meaning jokes, it's not difficult for actors. But slapstick is tough; what Charlie Chaplin did was extremely difficult. There are a lot of shades in comedy. 'Initially, creating Hansa's character was a bit difficult' Hansa has always been a people pleaser, isn't it (smiles)? I love Hansa, and it (playing her character) has been a fabulous journey. Before I started playing that character, preparing for it was a bit difficult. Hansa literally does nothing, and whenever she does anything, she creates a mess. So, how do you make her interesting for the audience? I had to work hard to make Hansa such an innocent person that the audience would believe in her. I am grateful that her innocence was accepted by the audience. I tried to ensure that Hansa comes across as a lovely, child-like person, like a loving baby. Tired of too many ads? go ad free now In real life, if a woman of Hansa's age behaves like that, you will probably slap her (laughs)! But I think we managed to create the kind of innocence that made audiences accept her whole-heartedly. Supriya Pathak with her actress-daughter Sanah Kapur 'Sanah's classmates would tease her in school, saying-Teri mom toh Hansa hai' When Sanah (her daughter) was young, her classmates in school would tease her, saying, 'Teri mom toh Hansa hai, unn ko toh kuch nahi aata. What do you guys eat? We are sure she doesn't even know how to cook.' It was quite funny because I am exactly the opposite in real life- a complete workaholic who is an expert at all household chores. Sanah would get very angry and tell them, 'No, my mama is not like that! She is a fabulous cook.' I am glad that the character found that kind of connect with the audience. Supriya's favourite comedies: Charlie Chaplin's films, Friends, The Big Bang Theory, Laurel and Hardy's films, Films of Marx Brothers, Khichdi, Sarabhai vs Sarabhai
